Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2017

Open Access 01-12-2017 | Research article

Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study

Authors: Dong S., Wang L., Guo Y. B., Ying H. F., Shen X. H., Meng Z. Q., Chen Hao, Chen Q. W., Li Z. S.

Published in: World Journal of Surgical Oncology | Issue 1/2017

Login to get access

Abstract

Background

Clinical prognostic parameters of liver metastasis from pancreatic adenocarcinoma have not been specifically identified.This study is to explore the risk factors of liver metastasis in advanced pancreatic adenocarcinoma (PDAC) patients in China.

Methods

A multicenter cohort study was conducted to explore whether liver metastasis in locally advanced and metastatic PDAC could be reflected by some common laboratory indexes. We collected 1787 advanced PDAC patients from three participating hospitals between 2004 and 2014. The associations between some laboratory indexes and risks of liver metastases were analyzed.

Results

Results have shown that 87% of stage IV patients developed synchronous liver metastasis. Primary tumor location (body/tail vs. head/neck, OR 0.55, 95% CI 0.36-0.83), primary tumor diameter (≥20 mm vs. <20 mm, OR 1.77, 95% CI 1.16–2.70), elevated ALT and AST (OR 1.62, 95% CI 0.92–2.83), and elevated CA19-9 (OR 2.72, 95% CI 1.85–3.99) upon diagnosis are significantly associated with risk of synchronous liver metastasis. Among stage III patients, 30.1% developed metachronous liver metastasis. However, no risk factors were identified among these patients.

Conclusions

Primary tumor location, diameter, elevated ALT and AST, and increased CA19-9 are independent risk factors of synchronous liver metastasis in PDAC patients.
Literature
1.
Singh D, Upadhyay G, Srivastava RK, Shankar S. Recent advances in pancreatic cancer: biology, treatment, and prevention. Biochim Biophys Acta. 2015;1856:13–27.
2.
Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7(3):163–72.
3.
Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L, Satolli MA. Current therapeutic strategies for advanced pancreatic cancer: a review for clinicians. World J Clin Oncol. 2016;7(1):27–43.CrossRefPubMedPubMedCentral
4.
Yuan Y, Hartland K, Boskovic Z, Wang Y, Walpita D, Lysy PA, Zhong C, Young DW, Kim YK, Tolliday NJ, Sokal EM, Schreiber SL, Wagner BK. A small-molecule inducer of PDX1 expression identified by high-throughput screening. Chem Biol. 2013;20(12):1513–22.CrossRefPubMedPubMedCentral
5.
Torphy RJ, Tignanelli CJ, Kamande JW, Moffitt RA, Herrera Loeza SG, Soper SA, Yeh JJ. Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma. PLoS ONE. 2014;9(2), e89474.CrossRefPubMedPubMedCentral
6.
7.
Wiltberger G, Bucher JN, Krenzien F, Benzing C, Atanasov G, Schmelzle M, Hau HM, Bartels M. Extended resection in pancreatic metastases: feasibility, frequency, and long-term outcome: a retrospective analysis. BMC Surg. 2015;15:126.CrossRefPubMedPubMedCentral
8.
Bouglouga O, Lawson-Ananissoh LM, Bagny A, Kaaga L, Redah D. Pancreatic cancer: epidemiological, clinical, and management aspects in the department of hepatogastroenterology at the Lome Campus teaching hospital (Togo). Med Sante Trop. 2015;25(3):323–6.PubMed
9.
Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–9.CrossRefPubMedPubMedCentral
10.
Li ZM, Peng YF, Du CZ, Gu J. Colon cancer with unresectable synchronous metastases: the AAAP scoring system for predicting the outcome after primary tumour resection. Colorectal Dis. 2016;18(3):255–63.
11.
Ng WW, Cheung YS, Wong J, Lee KF, Lai PB. A preliminary analysis of combined liver resection with new chemotherapy for synchronous and metachronous colorectal liver metastasis. Asian J Surg. 2009;32(4):189–97.CrossRefPubMed
12.
Wang X, Hershman DL, Abrams JA, Feingold D, Grann VR, Jacobson JS, Neugut AI. Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer. 2007;97(12):1606–12.CrossRefPubMedPubMedCentral
13.
Hwang SE, Yang DH, Kim CY. Prognostic factors for survival in patients with hepatic recurrence after curative resection of gastric cancer. World J Surg. 2009;33(7):1468–72.CrossRefPubMed
14.
Thelen A, Jonas S, Benckert C, Lopez-Hänninen E, Neumann U, Rudolph B, Schumacher G, Neuhaus P. Liver resection for metastatic gastric cancer. Eur J Surg Oncol. 2008;34(12):1328–34.CrossRefPubMed
15.
Hatwell C, Zappa M, Wagner M, Michoux N, Paradis V, Vilgrain V, Maggiori L, Panis Y. Detection of liver micrometastases from colorectal origin by perfusion CT in a rat model. Hepatobiliary Pancreat Dis Int. 2014;13(3):301–8.CrossRefPubMed
16.
Kawarada Y, Ishikura H, Kishimoto T, Kato H, Yano T, Kato H, Yoshiki T. The role of sialylated Lewis antigens on hematogenous metastases of human pancreas carcinoma cell lines in vivo. Pathol Res Pract. 2000;196(4):259–63.CrossRefPubMed
17.
18.
Kamisawa T, Isawa T, Koike M, Tsuruta K, Okamoto A. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas. 1995;11(4):345–9.CrossRefPubMed
19.
Fortner JG, Klimstra DS, Senie RT, Maclean BJ. Tumor size is the primary prognosticator for pancreatic cancer after regional pancreatectomy. Ann Surg. 1996;223(2):147–53.CrossRefPubMedPubMedCentral
20.
De Rooij T, Tol JA, Van Eijck CH, Boerma D, Bonsing BA, Bosscha K, Van Dam RM, Dijkgraaf MG, Gerhards MF, Van Goor H, van der Harst E, De Hingh IH, Kazemier G, Klaase JM, Molenaar IQ, Patijn GA, Van Santvoort HC, Scheepers JJ, van der Schelling GP, Sieders E, Busch OR, Besselink MG, Dutch Pancreatic Cancer Group. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis. Ann Surg Oncol. 2016;23(2):585–91.CrossRefPubMed
21.
Johnston WC, Hoen HM, Cassera MA, Newell PH, Hammill CW, Hansen PD, Wolf RF. Total pancreatectomy for pancreatic ductal adenocarcinoma: review of the National Cancer Data Base. HPB (Oxford). 2016;18(1):21–8.CrossRef
22.
Wang WL, Ye S, Yan S, Shen Y, Zhang M, Wu J, Zheng SS. Pancreaticoduodenectomy with portal vein/superior mesenteric vein resection for patients with pancreatic cancer with venous invasion. Hepatobiliary Pancreat Dis Int. 2015;14(4):429–35.CrossRefPubMed
23.
Gupta PK, Turaga KK, Miller WJ, Loggie BW, Foster JM. Determinants of outcomes in pancreatic surgery and use of hospital resources. J Surg Oncol. 2011;104(6):634–40.CrossRefPubMed
24.
Liles JS, Katz MH. Pancreaticoduodenectomy with vascular resection for pancreatic head adenocarcinoma. Expert Rev Anticancer Ther. 2014;14(8):919–29.CrossRefPubMed
25.
Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol. 2008;6(12):1301–8.CrossRefPubMed
26.
Da Rocha Lino A, Abrahão CM, Brandão RM, Gomes JR, Ferrian AM, Machado MC, Buzaid AC, Maluf FC, Peixoto RD. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis. J Gastrointest Oncol. 2015;6(5):511–5.PubMedPubMedCentral
27.
Choi Y, Oh DY, Kim K, Chie EK, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Ha SW, Bang YJ. Concurrent chemoradiotherapy versus chemotherapy alone for unresectable locally advanced pancreatic cancer: a retrospective cohort study. Cancer Res Treat. 2015.
28.
Wu L, Huang P, Wang F, Li D, Xie E, Zhang Y, Pan S. Relationship between serum CA19-9 and CEA levels and prognosis of pancreatic cancer. Ann Transl Med. 2015;3(21):328.PubMedPubMedCentral
29.
Matsumoto I, Murakami Y, Shinzeki M, Asari S, Goto T, Tani M, Motoi F, Uemura K, Sho M, Satoi S, Honda G, Yamaue H, Unno M, Akahori T, Kwon AH, Kurata M, Ajiki T, Fukumoto T, Ku Y. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: a multi-center retrospective study. Pancreatology. 2015;15(6):674–80.CrossRefPubMed
30.
Kanda M, Fujii T, Takami H, Suenaga M, Inokawa Y, Yamada S, Nakayama G, Sugimoto H, Koike M, Nomoto S, Kodera Y. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today. 2014;44(9):1692–701.CrossRefPubMed
31.
Nanashima A, Tobinaga S, Abo T, Hatano K, Takeshita H, Nonaka T, Hidaka S, Tanaka K, Kunizaki M, Sawai T, Yasutake T, Nagayasu T. Evaluation of surgical resection for pancreatic carcinoma at a Japanese single cancer institute. Hepatogastroenterology. 2012;59(115):911–5.PubMed
32.
Brown EG, Canter RJ, Bold RJ. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma. J Surg Oncol. 2015;111(3):293–8.CrossRefPubMed
33.
Alexakis N, Gomatos IP, Sbarounis S, Toutouzas K, Katsaragakis S, Zografos G, Konstandoulakis MM. High serum CA 19-9 but not tumor size should select patients for staging laparoscopy in radiological resectable pancreas head and peri-ampullary cancer. Eur J Surg Oncol. 2015;41(2):265–9.CrossRefPubMed
34.
Lai JC, Dodge JL, Sen S, Covinsky K, Feng S. Functional decline in patients with cirrhosis awaiting liver transplantation: results from the functional assessment in liver transplantation (FrAILT) study. [J] Hepatology. 2016;63(2):574.CrossRef
35.
Kim WR, Flamm SL, DiBisceglie AM, Bodenheimer HC, Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47(4):1363–70.CrossRefPubMed
36.
Carr BI, Guerra V. A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. Oncology. 2016;90(4):215–20.CrossRefPubMed
37.
Ellenrieder V, König A, Seufferlein T. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma. Digestion. 2016;94(1):44–9.
38.
39.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.CrossRefPubMedPubMedCentral
40.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, De la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.CrossRefPubMed
Metadata
Title
Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study
Authors
Dong S.
Wang L.
Guo Y. B.
Ying H. F.
Shen X. H.
Meng Z. Q.
Chen Hao
Chen Q. W.
Li Z. S.
Publication date
01-12-2017
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2017
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-017-1175-7

Other articles of this Issue 1/2017

World Journal of Surgical Oncology 1/2017 Go to the issue

Research

Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma

Research

Heavy alcohol drinking downregulates ALDH2 gene expression but heavy smoking up-regulates SOD2 gene expression in head and neck squamous cell carcinoma

Correspondence

Giant low-grade primary myofibroblastic sarcoma of the posterior chest wall

Research

Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment

Research

Mortality differences by surgical volume among patients with stomach cancer: a threshold for a favorable volume-outcome relationship

Case Report

Intraductal tubulopapillary neoplasm (ITPN) of the pancreas associated with an invasive component: a case report with review of the literature